Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al. YAP regulates HER3 signaling-driven adaptive resistance to RET inhibitors in RET-aberrant cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024
Kenji Morimoto, Ryosuke Hamashima, Tadaaki Yamada, Toshihide Yokoyama, Takehiko Kobayashi, Kazunari Tsuyuguchi, Takanori Kanematsu, Nobuyo Tamiya, Taisuke Tsuji, Ryota Nakamura, et al. Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy. Thoracic cancer. 2024. 15. 26. 1882-1888
Nobutaka Kataoka, Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Takayuki Takeda, Asuka Okada, Shinsuke Shiotsu, Yusuke Chihara, Osamu Hiranuma, Takahiro Yamada, et al. CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study. Translational lung cancer research. 2024. 13. 8. 1929-1937
Ryota Nakamura, Tadaaki Yamada, Shinsaku Tokuda, Kenji Morimoto, Yuki Katayama, Yohei Matsui, Soichi Hirai, Masaki Ishida, Hayato Kawachi, Ryo Sawada, et al. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer. Cancer letters. 2024. 598. 217124-217124
Yohei Matsui, Tadaaki Yamada, Yuki Katayama, Soichi Hirai, Ryo Sawada, Yusuke Tachibana, Masaki Ishida, Hayato Kawachi, Ryota Nakamura, Naoya Nishioka, et al. Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells. Cancer science. 2024
